link.springer.com

The Value of Serum CA 19-9 in Predicting Cholangiocarcinomas in Patients with Primary Sclerosing Cholangitis - Digestive Diseases and Sciences

  • ️Lindor, Keith D.
  • ️Thu Sep 01 2005

References

  1. Khan SA, Davidson BR, Goldin R, Pereira SP, Rosenberg WM, Taylor-Robinson SD, Thillainayagam AV, Thomas HC, Thursz MR, Wasan H: Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 51(Suppl 6):VI1–VI9, 2002

    PubMed  Google Scholar 

  2. Patel T: Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 33(6):1353–1357, 2001

    Article  CAS  PubMed  Google Scholar 

  3. Chapman RW: Risk factors for biliary tract carcinogenesis. Ann Oncol 10(Suppl 4):308–311, 1999

    PubMed  Google Scholar 

  4. Rosen CB, Nagorney DM, Wiesner RH, Coffey RJ, Jr, LaRusso NF: Cholangiocarcinoma complicating primary sclerosing cholangitis. Ann Surg 213(1):21–25, 1991

    CAS  PubMed  Google Scholar 

  5. Broome U, Olsson R, Loof L, Bodemar G, Hultcrantz R, Danielsson A, Prytz H, Sandberg-Gertzen H, Wallerstedt S, Lindberg G: Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 38(4):610–615, 1996

    CAS  PubMed  Google Scholar 

  6. Aadland E, Schrumpf E, Fausa O, Elgjo K, Heilo A, Aakhus T, Gjone E: Primary sclerosing cholangitis: A long-term follow-up study. Scand J Gastroenterol 22(6):655–664, 1987

    CAS  PubMed  Google Scholar 

  7. Bergquist A, Glaumann H, Persson B, Broome U: Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: A case-control study. Hepatology 27(2):311–316, 1998

    Article  CAS  PubMed  Google Scholar 

  8. Broome U, Lofberg R, Veress B, Eriksson LS: Primary sclerosing cholangitis and ulcerative colitis: Evidence for increased neoplastic potential. Hepatology 22(5):1404–1408, 1995

    Article  CAS  PubMed  Google Scholar 

  9. Siqueira E, Schoen RE, Silverman W, Martin J, Rabinovitz M, Weissfeld JL, Abu-Elmaagd K, Madariaga JR, Slivka A, Martini J: Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. Gastrointest Endosc 56(1):40–47, 2002

    Article  PubMed  Google Scholar 

  10. Rogers SA, Podolsky DK: Predicting cholangiocarcinoma in patients with primary sclerosing cholangitis: An analysis of the serological marker CA 19-9. Hepatology 19(2):543–545, 1994

    Article  CAS  PubMed  Google Scholar 

  11. Fisher A, Theise ND, Min A, Mor E, Emre S, Pearl A, Schwartz ME, Miller CM, Sheiner PA: CA19-9 does not predict cholangiocarcinoma in patients with primary sclerosing cholangitis undergoing liver transplantation. Liver Transpl Surg 1(2):94–98, 1995

    Article  CAS  PubMed  Google Scholar 

  12. Reeves ME, DeMatteo RP: Genes and viruses in hepatobiliary neoplasia. Semin Surg Oncol 19(2):84–93, 2000

    Article  CAS  PubMed  Google Scholar 

  13. Maestranzi S, Przemioslo R, Mitchell H, Sherwood RA: The effect of benign and malignant liver disease on the tumour markers CA19-9 and CEA. Ann Clin Biochem 35(Pt 1):99–103, 1998

    PubMed  Google Scholar 

  14. Nichols JC, Gores GJ, LaRusso NF, Wiesner RH, Nagorney DM, Ritts RE, Jr.: Diagnostic role of serum CA 19-9 for cholangiocarcinoma in patients with primary sclerosing cholangitis. Mayo Clin Proc 68(9):874–879, 1993

    CAS  PubMed  Google Scholar 

  15. Ramage JK, Donaghy A, Farrant JM, Iorns R, Williams R: Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterology 108(3):865–869, 1995

    Article  CAS  PubMed  Google Scholar 

  16. Chalasani N, Baluyut A, Ismail A, Zaman A, Sood G, Ghalib R, McCashland TM, Reddy KR, Zervos X, Anbari MA, Hoen H: Cholangiocarcinoma in patients with primary sclerosing cholangitis: A multicenter case-control study. Hepatology 31(1):7–11, 2000

    Article  CAS  PubMed  Google Scholar 

  17. Patel AH, Harnois DM, Klee GG, LaRusso NF, Gores GJ: The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol 95(1):204–207, 2000

    Article  CAS  PubMed  Google Scholar 

  18. Bjornsson E, Kilander A, Olsson R: CA 19-9 and CEA are unreliable markers for cholangiocarcinoma in patients with primary sclerosing cholangitis. Liver 19(6):501–508, 1999

    CAS  PubMed  Google Scholar 

  19. Hultcrantz R, Olsson R, Danielsson A, Jarnerot G, Loof L, Ryden BO, Wahren B, Broome U: A 3-year prospective study on serum tumor markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. J Hepatol 30(4):669–673, 1999

    Article  CAS  PubMed  Google Scholar 

  20. Mann DV, Edwards R, Ho S, Lau WY, Glazer G: Elevated tumour marker CA19-9: Clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol 26(5):474–479, 2000

    Article  CAS  PubMed  Google Scholar 

  21. Giannini E, Borro P, Botta F, Chiarbonello B, Fasoli A, Malfatti F, Romagnoli P, Testa E, Risso D, Lantieri PB, Antonucci A, Boccato M, Milone S, Testa R: Cholestasis is the main determinant of abnormal CA 19-9 levels in patients with liver cirrhosis. Int J Biol Markers 15(3):226–230, 2000

    CAS  PubMed  Google Scholar 

  22. Fletcher R, Fletcher S, Wagner E: Clinical Epidemiology: The Essenctials. Third ed. Philadelphia: Williams & Williams, 1996.

Download references